Malignant Solid Tumor clinical trials

Explore recruiting malignant solid tumor clinical trials.

Recruiting malignant solid tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Malignant Solid Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid tumors

Belgium, Netherlands, Spain, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan

Spain, Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

First in Human Study of TOS-358 in Adults with Soid Tumors

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

[14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

Hungary, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

First-In-Human, Open-Label, Dose Escalation Trial with Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects with Malignant Solid Tumors.

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Malignant Solid Tumor trials by city

Malignant Solid Tumor in Toronto Malignant Solid Tumor in Vancouver Malignant Solid Tumor in Montreal Malignant Solid Tumor in Calgary Malignant Solid Tumor in Edmonton Malignant Solid Tumor in Ottawa Malignant Solid Tumor in Winnipeg Malignant Solid Tumor in Quebec City Malignant Solid Tumor in Hamilton Malignant Solid Tumor in Kitchener Malignant Solid Tumor in London Malignant Solid Tumor in Halifax Malignant Solid Tumor in New York Malignant Solid Tumor in Los Angeles Malignant Solid Tumor in Chicago Malignant Solid Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease